Life After FDA: Rachel Sherman To Tackle Real World Evidence, Clinical Trial Efficiency
Executive Summary
Sherman, who left the No. 2 post at FDA in January, is working part-time at Duke-Margolis and serving as a consultant to Medidata Solutions.
You may also be interested in...
Sanofi/Google Alliance To Apply Big Data To R&D, Commercial And Marketing Operations
Sanofi says the virtual innovation lab it will create with Google will enable precision health care and optimize R&D and commercial operations. Incoming CEO Hudson has been tasked with improving the pharma’s R&D and digital capabilities.
AI And Big Data In Focus: What Is Preventing Faster Adoption In Health Care Settings?
To the wider public and even governments, big data, predictive analytics and machine learning might appear to be recent phenomena that suddenly hold the answers to most of the health care delivery problems. But those who have been generating the debate and charting future adoption over the past several years know it is not as simple as that.
What Does Rachel Sherman Think About Top FDA Regulatory Issues?
Speaking at the BIO CEO & Investor Conference, US agency's No. 2 official talks about compassionate use, opioids, clinical trial design, and the agency's succession plan.